retatrutide news october 2025 and the Grey Market: Buyer Beware – Sarah Hormachea Breaking news: Lilly’s triple agonist

XIGDUO XR is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m [see CONTRAINDICATIONS ]

Supplement Facts Reviews represent the opinions of the authors and have not been modified in any way

The Food and Drug Administration label for semaglutide the active ingredient in many weight loss drugs says it may increase the risk of bone fractures in older adults and women

Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome Gut Microbes 2026;18(1):2690689 doi:10.1080/19490976.2026.2690689 (Human trial) Written by Ali Rza Akn Microbiome Scientist, Author & Founder of Next-Microbiome Ali Rza Akn is a microbiome scientist with nearly 30 years of experience in translational biotechnology, systems biology, and applied microbiome research, spanning discovery, preclinical development, and clinical-stage translation

Previously, there had only been one oral drug for this indication: metformin, which was approved in 2000

The North America GLP-1 receptor agonist market dominated the revenue with 75.46% share in 2025, supported by a high prevalence of metabolic disorders, early adoption of novel therapeutics, and a well-established healthcare infrastructure